Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review

Laura G. Draijer1,2,3 | Janneke P. M. van Oosterhout1 | Yasaman Vali4 | Sabrina Zwetsloot1 | Johanna H. van der Lee5,6 | Faridi S. van Etten-Jamaludin7 | Malika Chegary8 | Marc A. Benninga1 | Bart G. P. Koot1

1Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers, Academic Medical Center, Emma Children's Hospital, University of Amsterdam, Amsterdam, The Netherlands
2Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, Academic Medical Center, Emma Children's Hospital, Amsterdam, The Netherlands
3Amsterdam UMC, University of Amsterdam, Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, Netherlands
4Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5Paediatric Clinical Research Office, Amsterdam University Medical Centers, Academic Medical Center/Emma Children's Hospital, University of Amsterdam, Amsterdam, The Netherlands
6Knowledge Institute of the Dutch Federation of Medical Specialists, Utrecht, The Netherlands
7Amsterdam UMC, University of Amsterdam, Research Support, Medical Library AMC, Amsterdam, The Netherlands
8Department of Paediatrics, Onze Lieve Vrouwe Gasthuis Hospital, Amsterdam, The Netherlands

Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in children. Even at young age, it can progress to liver fibrosis. Given the drawbacks of liver biopsy, there is a need for non-invasive methods to accurately stage liver fibrosis in this age group. In this systematic review, we evaluate the diagnostic accuracy of non-invasive methods for staging liver fibrosis in children with NAFLD.

Methods: We searched MEDLINE, Embase, Web of Science and the Cochrane Library, for studies that evaluated the performance of a blood-based biomarker, prediction score or imaging technique in staging liver fibrosis in children with NAFLD, using liver biopsy as the reference standard.

Results: Twenty studies with a total of 1787 NAFLD subjects were included, which evaluated three prediction scores, five simple biomarkers, two combined biomarkers and six imaging techniques. Most studies lacked validation. Substantial heterogeneity

Abbreviations: ALT, alanine aminotransferase; AUC, area under the receiver operating characteristics curve; CK-18, cytokeratin-18; ELF test, enhanced liver fibrosis test; GGT, gamma glutamyl transferase; HA, hyaluronic acid; LR−, negative likelihood ratio; LR+, positive likelihood ratio; MCP-1, monocyte chemoattractant protein 1; MRE, magnetic resonance elastography; NAFLD, non-alcoholic fatty liver disease; NASH CRN, NASH Clinical Research Network; NPV, negative predictive value; PAI-1, plasminogen activator inhibitor 1; PIINP, procollagen type III amino terminal peptide; PNFI, paediatric NAFLD fibrosis index; PPV, positive predictive value; QUADAS-2, quality Assessment of Diagnostic Accuracy Studies 2; SWE, shear wave elastography; TE, transient elastography.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
of studies and limited available study data precluded a meta-analysis of the few fibrosis tests evaluated in more than one study. The most consistent accuracy data were found for transient elastography by FibroScan®, ELF test and ultrasound elastography, with an area under the receiver operating characteristics curve varying between 0.92 and 1.00 for detecting significant fibrosis.

**Conclusion:** Due to the lack of validation, the accuracy and clinical utility of non-invasive fibrosis tests in children with NAFLD remains uncertain. As studies have solely been performed in tertiary care settings, accuracy data cannot directly be translated to screening populations.

**Key words**
diagnosis, hepatic fibrosis, obesity, paediatric

---

**1 | INTRODUCTION**

Due to the obesity epidemic, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in children and adults. The pooled prevalence of NAFLD in children with obesity is 34% (95% CI: 27.8% to 41.2%). Simple steatosis, or non-alcoholic fatty liver (NAFL), is the first stage of the NAFLD spectrum and is defined as fat accumulation in more than 5% of the hepatocytes in the biopsy specimen on histological evaluation. A NAFLD subtype that is characterized by significant inflammation is categorized as non-alcoholic steatohepatitis (NASH) and can progress to severe stages of fibrosis and cirrhosis. Although most children with NAFLD will have simple steatosis, advanced fibrosis is reported in up to 17% of children referred to liver centres after screening, and some cases of NAFLD-related cirrhosis in children have been reported. Evidence shows that fibrosis is the most important predictor for liver-related complications in adults, such as liver failure and hepatocellular carcinoma, and is associated with increased overall mortality. Therefore, liver fibrosis represents the most clinically relevant determinant of long-term outcomes in this disorder. The development of fibrosis at a young age is considered worrisome and, although long-term longitudinal studies are lacking to prove this, could be related to a higher risk of developing long-term liver and non-liver complications. Current paediatric guidelines recommend screening for fibrosis in children with NAFLD but do not specify what test should be used to assess fibrosis. In addition, accurate tests could serve as surrogate endpoints in future paediatric therapeutic trials.

Liver biopsy is the current reference standard to determine the stage of liver fibrosis in patients with NAFLD. However, in addition to the risk of complications, the costly and invasive nature of this procedure makes it unsuitable for screening purposes or for monitoring disease progression in this highly prevalent disorder. Moreover, the diagnostic accuracy of liver biopsy is not optimal due to sampling variability caused by the often patchy distribution of NAFLD in the liver and interobserver and intraobserver variability of the histological interpretation. Therefore, there is an urgent need for accurate, safe and cost-effective alternatives to accurately stage liver fibrosis in patients with NAFLD. Over the past decade, many fibrosis tests have been developed, ranging from simple laboratory tests to more complex biomarkers or prediction scores as well as imaging techniques. Although most of these tests were developed and validated in the adult population, several research groups have investigated their utility in the paediatric population. This systematic review aims to appraise the diagnostic accuracy of non-invasive methods for detecting and staging liver fibrosis in children with NAFLD.

**2 | METHODS**

**2.1 | Literature search strategy**

A sensitive search strategy was developed in collaboration with an experienced medical librarian and conducted in PubMed/MEDLINE, Ovid/EMBASE, Web of Science and Cochrane Library (Data S1 and S2). The search comprised the following search terms: Non-alcoholic
2.2 | Selection criteria

Articles were included if they fulfilled the following criteria: (a) the study included patients with biopsy proven NAFLD/NASH/steato-
sis, and in case of inclusion of other causes of chronic liver disease, the study provided discrete data on the NAFLD population sepa-
rately; (b) the study consisted of children up to 18 years, or reported separately on children, if adults were included; (c) the study evaluated the performance of a blood-based biomarker, prediction score or imaging technique to detect different stages of liver fibrosis; (d) liver biopsy was used as the reference test; (e) the study included ≥60 participants or the diagnostic test was reported in ≥2 studies; and (f) the study provided enough data to construct a 2 × 2 table. Studies were excluded if they did not meet the inclusion criteria or (a) had a case report, case series, conference abstract or commentary design and (b) were conducted in animal subjects. No language restriction was used.

2.3 | Data extraction and quality assessment

Two authors (L.D. and J.O.) independently screened the titles and abstracts to identify articles that met the inclusion criteria using Rayyan software (https://rayyan.qcri.org). Then, the full texts of the potentially eligible studies were screened independently by the two authors. Data extraction was performed independently by two authors (L.D. and S.Z.) using a predesigned data extraction form. For studies that included adults or patients with various liver diseases as well, that did not report paediatric data or NAFLD data separately, the authors were contacted and requested to provide raw data. The study design, patients characteristics, histological scoring system that was used for fibrosis staging, prevalence of different fibrosis stages and accuracy data of different diagnostic methods (thresholds, number of true positives [TP], false positives [FP], true negatives [TN], false negatives [FN], sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV]) and [if provided] the area under the receiver operating character-
istics curve (AUC) were extracted from each included article. For uniformity, the fibrosis stages assessed by a histological scoring system other than NASH Clinical Research Network (CRN) were converted to fibrosis stages according to NASH CRN.15 The different fibrosis scoring systems are presented in Data S3. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to evaluate the methodological quality of the included studies. Any disagreement between the two authors (L.D. and J.O.) was resolved through discussion. A third reviewer (B.K.) was consulted when necessary.

2.4 | Data analysis

Medcalc was used to analyse the tests for sensitivity, specificity, PPV, NPV, positive likelihood ratio (LR+) and negative likelihood ratio (LR−).16 Review Manager version 5.3 was used for quality assessment and creating figures. A meta-analysis of any of the evaluated fibrosis tests could not be performed because a summary ROC curve (HSROC) and summary sensitivities and specificities could not be constructed due to the use of different reported thresholds and different settings of magnetic resonance elastography (MRE) and ultrasound elastography among studies.

3 | RESULTS

3.1 | Search results

A total of 3674 records were retrieved from our search. After removing duplicates, 2641 records were retained. After screening the titles and abstracts, full text of 125 articles were reviewed of which 20 studies met our inclusion criteria. Reasons for exclusion of the 105 records are shown in Figure 1. Six of the excluded studies did not report sufficient data to create 2 × 2 tables but reported the AUCs. Data S4 shows the AUCs of these six excluded studies and of four included studies that, in addition to tests with data to create a 2 × 2 table, reported AUCs of different thresholds or various types of tests. The included studies evaluated three prediction scores, five simple biomarkers, two combined biomarkers and six imaging techniques.

3.2 | Study characteristics

Characteristics of the 20 included studies are provided in Table 1. All studies were performed in tertiary hospitals of which eight were paediatric liver transplant centres. All studies had a cross-sectional design. Sixteen studies used prospectively collected data, one study used retrospectively collected data and in three studies, this was not specified. Thirteen studies reported on the accuracy of detecting mild fibrosis (≥F1),17-28 10 studies on detecting significant fibrosis (≥F2)19,20,24,25,29-34 and nine studies on detecting advanced fibrosis (≥F3).19,20,24,28,30,31,35-37 The time interval between the index test and liver biopsy varied between 0 days and 6 months.

3.3 | Patient characteristics

In total, 1787 subjects with NAFLD were included. The mean age of the NAFLD patients ranged from 8.5 to 14.1 years and 64% were male (range 24% to 80%). The prevalence ranged from 37% to 98% per study for ≥F1,17,30,32,36,37 40% to 48% for ≥F217,19,22,24-34,36 and 3% to 40% for ≥F317,22,24,31,35-37 based on the 17 studies that reported separate prevalence data.
3.4 | Methodological quality assessment

The results of the methodological quality assessment of the individual studies using the QUADAS-2 tool are presented in Figure 2 and are summarized in Figure 3. Only three studies had a low risk of bias in all four domains. In all studies, there were concerns about applicability regarding patient selection because patients were recruited in tertiary hospitals and were selected to undergo liver biopsy based on clinical grounds. In two studies, there were concerns about applicability regarding the index test. These tests evaluated time-harmonic elastography: a technique developed by Hudert et al. which is not commercially available and the S-probe of the FibroScan® (Echosens, France) that was evaluated in children with overweight/obesity by Alkhouri et al. This specific probe was developed for children with a chest circumference < 75 cm and is generally unsuitable for children with obesity.

3.5 | Detecting mild fibrosis (≥F1)

Thirteen studies investigated non-invasive methods to detect mild fibrosis (≥F1). These studies addressed prediction scores, that is, cytokerin-18 (CK-18) combined with waist circumference and the paediatric NAFLD fibrosis index (PNFI), which is based on age, waist circumference and triglycerides. The evaluated biomarkers were the enhanced liver fibrosis (ELF) test, hyaluronic acid (HA), CK-18 and the combination of CK-18 and HA. The imaging techniques evaluated were MRE, transient elastography (TE) of FibroScan®, shear wave elastography (SWE), time-harmonic elastography and point shear wave elastography. The results of these 13 studies are presented in Table 2.

Among the prediction scores and biomarkers, only the three studies using the ELF test alone or combined with PNFI showed an AUC greater than 0.90. However, the optimal threshold for the ELF test alone as reported by Nobili et al. (9.28) could not be reproduced by Alkhouri et al. who reported a far lower optimal threshold (8.49). All other evaluated biomarkers had a lower AUC and reported either a low sensitivity or specificity at their optimal threshold. The PNFI is the only test with accuracy data reported at a wide range of thresholds. Nobili et al. found that a score < 3 could be used to rule out fibrosis with a sensitivity of 96%, and a score of ≥9 could be used to rule in fibrosis with a specificity of 98%. However, this resulted in 56% of patients with an undetermined classification. Alkhouri et al. validated these thresholds with similar accuracy results and 52% with an undetermined classification. He subsequently combined the PNFI with the ELF test for patients with an undetermined classification, which resulted in classifying all patients with an overall sensitivity of 86% and specificity of 89%.

Most imaging techniques showed higher accuracy than prediction scores and biomarkers for detecting mild fibrosis. Near perfect accuracy was reported for TE of FibroScan® (AUC 0.98, 95% CI: 0.90-0.99) resulting in a sensitivity and specificity of both >90% at a threshold of 5.1 kPa in the only study available.

None of the studies validated their results externally. Three studies performed internal cross-validation using bootstrapping. The
| Author, year | Country, hospital | Setting | Inclusion period | Population | Histological scoring system | Time interval | Index test(s) | N (total) | Target condition(s)/N (%) | Male, n (%) | Mean age, years (SD) | Mean BMI z score (SD) or BMI percentile (SD) | Mean ALT, IU/L (SD) | Mean HOMA-IR (SD) |
|--------------|-------------------|---------|-----------------|------------|-----------------------------|--------------|---------------|-----------|-------------------------|-------------|----------------------|---------------------------------|------------------|-------------------|
| Fitzpatrick, 2012 | UK, London | Tertiary Hospital/Liver Transplant Centre | NR | Biopsy proven NAFLD | NASH CRN | NR | - PAI-1 | 40 | ≥F3/13 (33) | 30 (75) | 13.4 (11.5-15.2) | 2.12 (1.77-2.31) | 67 (50-83) | 4.08 (2.18-5.89) |
| Fitzpatrick, 2010 | UK, London | Tertiary Hospital/Liver Transplant Centre | NR | Biopsy proven NAFLD | NASH CRN | Within 3 months | CK-18 (M30) | 45 | ≥F2/23 (51) | 25 (57) | 12.7 (10.2-14.3) | 1.7 (1.2-2.1) | 61 (23-178) | 0.68 (0.55-0.94) |
| Mandelia, 2016 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2008-2011 | Biopsy proven NAFLD | NASH CRN | 0 days | CK-18 (M30) | 201 | ≥F1/136 (68) | 74 (37) | 10.7 (2.5) | 97 (93-98) | 70 (50-87) | 2.6 (1.7) |
| Lebenschtejn, 2011 | Poland, Białystok | Tertiary Hospital/Liver Transplant Centre | NR | Biopsy proven NAFLD | Brunt & Kleiner | 1 day | HA - CK-18 (M30) | 52 | ≥F1/19 (37) | 39 (75) | 12.1 (10.5-14.4) | NR | 70 (51-114) | 1.9 (0.3-3.7) |
| Nobili, 2010 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2006-2009 | Biopsy proven NAFLD | NASH CRN | 0 days | HA | 100 | ≥F1/65 (65) | ≥F2/15 (15) | 68 (68) | NR | NR | NR | NR |
| Mosca, 2019 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2015-2018 | Biopsy proven NAFLD | NASH CRN | NR | PIINP | 204 | ≥F2/45 (22) | ≥F3/7 (3) | 154 (76) | 13.1 (2.2) | NR | 28 (19-46) | 3.6 (2.1-4.4) |
| Alkhouri, 2011 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2007-2009 | Biopsy proven NAFLD | NASH CRN | NR | - ELF test (Guha algorithm) | 111 | ≥F1/76 (68) | 73 (67) | 10.5 (9.5-11.4) | 97 (93-98) | 67 (45-89) | 2.4 (1.6-3.6) |
| Nobili, 2009 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2004-2006 | Biopsy proven NAFLD | Brunt & Kleiner | 3 days | ELF test (Guha algorithm) | 112 | ≥F1/75 (67) | ≥F2/17 (15) | ≥F3/8 (7) | 64 (57) | 13.8 (3.3) | 1.8 (0.6) | 80 (63) | 2.5 (1.1) |
| Alkhouri, 2014 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | NR | Biopsy proven NAFLD | NASH CRN | 1 week | PNFS | 242 | ≥F3/36 (17) | 90 (37) | 12.4 (3.1) | 93 (13) | 75 (55-99) | 2.2 (1.4-3.2) |
| Nobili, 2009 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2004-2008 | Biopsy proven NAFLD | NASH CRN | NR | PNFI | 203 | ≥F1/141 (69) | 136 (67) | 11.9 (2.8) | 1.8 (0.7) | 67 (61) | 2.4 (1.9) |

(Continues)
| Author, year | Country, hospital | Setting | Inclusion period | Population | Histological scoring system | Time interval | Index test(s) | N° (total = 1787) | Target condition(s)/N (%) | Male, n (%) | Mean age, years (SD) | Mean BMI z score (SD) or BMI percentile (SD) | Mean ALT, IU/L (SD) | Mean HOMA-IR (SD) |
|--------------|------------------|---------|-----------------|------------|-----------------------------|--------------|--------------|------------------|----------------------------|-------------|---------------------|---------------------------------------------|----------------|-------------------|
| Alkhouri, 2013 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2006-2011 | NR | Biopsy proven NAFLD | NASH CRN | TE (FibroScan® S-probe®) | 67 | ≥F2/10 (15) 46 (69) 8.5 (2.4) | NR | 83 (55) | NR |
| Lee, 2013 | USA, Boston | Tertiary Hospital/Liver Transplant Centre | 2006-2011 | Various liver diseases | METAVIR | Within 6 months | 10 | ≥F3/4 (40) 5 (50) 13.9 (2.4) | 2.12 (0.40) | NR | NR |
| Nobili, 2008 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2007-2008 | Biopsy proven NASH | Brunt & Kleiner | Within 6 months | TE (FibroScan® M-probe) | 50 | ≥F1/39 (78) | 31 (62) 13.1 (2.0) | NR | 72 (38) |
| Hudert, 2018 | Germany, Berlin | Tertiary Hospital | 2014-2017 | Suspected NASH | NASH CRN | NR | Time-harmonic elastography | 67 | ≥F1/48 (72) | 51 (76) 14.1 (2.2) | 2.8 (0.6) | 108 (70) | 6.9 (3.7) |
| Phelps, 2016 | USA, San Francisco | Tertiary Hospital | 2014-2015 | Various liver diseases | METAVIR and NASH CRN | 0 days | Point SWE (Siemens Acuson S3000) | 5 | ≥F1/4 (80) | 3 (60) 11.2 (2.7) | NR | 154 (93) | NR |
| Garcovich, 2017 | Italy, Rome | Tertiary Hospital/Liver Transplant Centre | 2015 | Biopsy proven NASH | Brunt | Within 6 months | SWE (Aixplorer US system) | 68 | ≥F2/16 (24) | 37 (54) 12.6 (2.5) | NR | 41 (26) | 4.5 (2.1) |
| Farmakis, 2019 | USA, St. Louis | Tertiary Hospital | 2015-2018 | Various liver diseases | METAVIR, Ishak and NASH CRN | Within 1 month | 2D-SWE (GE LOGIQ E9 system) | 33 | ≥F1/26 (79) | 24 (73) 13.3 (3.4) | NR | 150 (104) | NR |
| Schwimmer, 2017 | USA, San Diego and Texas | Tertiary Hospital | NR | Biopsy proven NAFLD | NASH CRN | Within 6 months | 2D MR Elastography | 90 | ≥F1/36 (40) | 66 (73) 13.1 (2.4) | 2.1 (0.3) | NR | NR |
| Trout, 2018 | USA, Cincinnati | Tertiary Hospital | 2012-2016 | Various liver diseases | NASH CRN | Within 3 months | MR Elastography | 44 | ≥F2/23 (52) | NR | NR | NR | NR |
| Hudert, 2019 | Germany, Berlin | Tertiary Hospital | 2014-2016 | Obese/overweight suspected NASH | NASH CRN | NR | Multifrequency MRE | 50 | ≥F1/35 (70) | 40 (80) 14.1 (2.1) | 2.7 (0.6) | 109 (67) | 6.5 (3.1) |

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CK-18, cytokeratin 18; ELF test, enhanced liver fibrosis test; HA, hyaluronic acid; HOMA-IR, homeostatic model assessment for insulin resistance; MCP-1, monocyte chemoattractant protein 1; MRE, magnetic resonance elastography; NAFLD, non-alcoholic fatty liver disease; NASH CRN, non-alcoholic steatohepatitis Clinical Research Network; NR, not reported; PAI, plasminogen activator inhibitor 1; PIIINP, procollagen type III amino terminal peptide; PNFI, paediatric NAFLD fibrosis index; PNFS, paediatric NAFLD fibrosis score; SWE, shear wave elastography; TE, transient elastography.

*Number of patients with NAFLD.

*Time interval between liver biopsy and index test.

*Median with IQR.
use of different optimal thresholds reported in the different studies on HA and imaging techniques prevented comparison of accuracy findings among studies in this systematic review. Only the PNFI and ELF test could be compared between studies, yielding discordant results for the optimal threshold in the latter as described above.

3.6 | Detecting significant fibrosis (≥F2)

Ten studies evaluated the accuracy of non-invasive methods to detect significant fibrosis (≥F2). These studies addressed the prediction score PFNI, the biomarkers HA, CK-18 and procollagen type III amino terminal peptide (PIIINP) and the imaging techniques MRE, TE of Fibroscan®, time-harmonic elastography and SWE. Table 3 presents the results of these ten studies.

Among the biomarkers, the ELF test showed a remarkably high AUC (0.98, 95% CI: 0.96-1.00) resulting in a sensitivity of 94% and specificity of 93% at a threshold of 10.18 in the only study available.24 High AUCs were also reported for two of the three components of the ELF test: HA and PIIINP.25,30

TE of FibroScan® was evaluated by Alkhouri et al. and Nobili et al., and both reported an excellent AUC close to 1.00 with a sensitivity of 100% in both studies and a specificity of 92% and 100%, respectively, at slightly different optimal thresholds while using different probes (8.2 kPa with S-probe34 and 7.4 kPa with M-probe,23 respectively). The two evaluated shear wave elastography methods showed high AUCs with high specificity and a sensitivity of >70%.19,32 Trout et al. reported an AUC of 0.53 (95% CI: 0.35-0.71) for MRE using one frequency (60 Hz) for the external vibrations, while Hudert et al. reported an AUC of 0.91 (95% CI: 0.83-0.99) using seven frequencies (30-60 Hz).20,29

None of the studies used an external validation cohort. Only one study performed internal validation using bootstrapping.25 Only for imaging techniques (TE of Fibroscan®, MRE and ultrasound elastography) multiple studies were included; however, pooling of results was not feasible due to the use of different optimal thresholds, FibroScan® probes, MRE settings and ultrasound elastography techniques.

3.7 | Detecting advanced fibrosis (≥F3)

Nine studies evaluated the accuracy of non-invasive methods to detect advanced fibrosis (≥F3). These studies addressed the prediction score paediatric NAFLD fibrosis score (PNFS) which is based on alanine aminotransferase (ALT), platelet counts and gamma glutamyl transferase (GGT). The evaluated biomarkers were monocyte chemoattractant protein 1 (MCP-1), plasminogen activator inhibitor 1 (PAI-1) and PIIINP, and the imaging techniques were MRE, TE of FibroScan® and time-harmonic elastography. Table 4 presents the results of these nine studies.

Again, among the biomarkers, the ELF test showed a near perfect accuracy (AUC 0.99, 95% CI: 0.97-1.00) in the only included study by Nobili et al.24 Its component PIIINP had an equally near perfect AUC of 0.99 (95% CI: 0.98-1.00),30 while HA, another component of the ELF test, showed a mediocre AUC of 0.73 (95%
**TABLE 2**  Studies on detecting mild fibrosis

| Study               | Test                              | AUC (95% CI)       | Threshold | TP  | FP  | FN  | TN  | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|---------------------|-----------------------------------|--------------------|-----------|-----|-----|-----|-----|----------------------|----------------------|--------------|--------------|
| **Prediction scores** |                                   |                    |           |     |     |     |     |                      |                      |              |              |
| Nobili, 2009        | PNFI                              | 0.85 (0.80-0.90)   | ≥1        | 140 | 58  | 1   | 4   | 96 (91-98)           | 29 (18-42)           | 75 (68-81)   | 75 (53-90)   |
|                     |                                   |                    | ≥2        | 137 | 53  | 5   | 9   | 97 (93-99)           | 145 (72-26)          | 72 (65-78)   | 69 (39-91)   |
|                     |                                   |                    | ≥3        | 135 | 44  | 6   | 18  | 96 (91-98)           | 29 (18-42)           | 75 (68-82)   | 75 (53-90)   |
|                     |                                   |                    | ≥4        | 132 | 35  | 9   | 27  | 94 (88-97)           | 44 (31-57)           | 79 (72-85)   | 75 (58-88)   |
|                     |                                   |                    | ≥5        | 125 | 29  | 16  | 33  | 88 (82-93)           | 53 (40-66)           | 81 (74-87)   | 67 (53-80)   |
|                     |                                   |                    | ≥6        | 115 | 23  | 26  | 39  | 82 (74-88)           | 63 (50-75)           | 83 (76-89)   | 60 (47-72)   |
|                     |                                   |                    | ≥7        | 108 | 10  | 33  | 52  | 77 (69-83)           | 84 (72-92)           | 92 (85-96)   | 61 (50-72)   |
|                     |                                   |                    | ≥8        | 88  | 6   | 53  | 56  | 62 (54-70)           | 90 (80-96)           | 94 (87-98)   | 51 (42-61)   |
|                     |                                   |                    | ≥9        | 65  | 1   | 76  | 61  | 46 (38-55)           | 98 (91-100)          | 99 (92-100)  | 45 (36-53)   |
| Alkhouri, 2011      | PNFI                              | 0.761 (0.661-0.861)| ≥3.47a    | 71  | 24  | 5   | 11  | 93 (85-98)           | 31 (17-49)           | 75 (70-79)   | 69 (45-85)   |
|                     |                                   |                    | ≥9b       | 34  | 3   | 42  | 32  | 45 (33-57)           | 91 (77-98)           | 92 (79-97)   | 43 (38-49)   |
|                     | PNFI + ELF                         | 0.994 (0.917-0.99) | If PNFI is between 3.47 and 9, use ELF test with a threshold of 8.49 | 65  | 4   | 11  | 31  | 86 (76-93)           | 89 (73-97)           | 94 (62-83)   | 74 (62-83)   |
| Mandelia, 2016      | CK-18 (M30) + waist circumference  | 0.842 (0.785-0.900)|(validation model 0.839)| ≥35g | 132 | 40  | 4   | 25  | 97 (93-99)           | 38 (27-51)           | 77 (73-80)   | 86 (69-95)   |
|                     |                                   |                    | ≥82d      | 80  | 8   | 56  | 57  | 59 (50-67)           | 88 (77-95)           | 91 (84-95)   | 50 (45-56)   |
| **Biomarkers**      |                                   |                    |           |     |     |     |     |                      |                      |              |              |
| Lebensztejn, 2011   | CK-18 (M30)                        | 0.666              | ≥201 u/Lf | 15  | 13  | 4   | 20  | 79 (54-94)           | 61 (42-77)           | 54 (42-65)   | 83 (67-93)   |
|                     | HA                                | 0.672              | ≥19.1 ng/mLg | 16  | 15  | 3   | 18  | 84 (60-97)           | 55 (36-72)           | 52 (41-92)   | 86 (67-95)   |
|                     | HA + CK-18 (M30)                   | 0.73               | HA ≥ 19.1 ng/mL + CK-18 ≥ 201 u/L | 14  | 7   | 5   | 26  | 74 (49-91)           | 79 (61-91)           | 67 (50-80)   | 84 (71-92)   |
| Nobili, 2010        | HA                                | 0.88 (0.81-0.96)   | ≥1200 ng/mLh | 40  | 2   | 27  | 31  | 60 (47-72)           | 94 (80-99)           | 90 (77-97)   | 53 (39-66)   |
| Nobili, 2009        | ELF test                          | 0.92 (0.86-0.97)   | ≥9.19     | 68  | 13  | 7   | 24  | 91 (82-96)           | 65 (47-80)           | 84 (77-89)   | 77 (62-88)   |
|                     |                                   |                    | ≥9.28d    | 66  | 7   | 9   | 30  | 88 (78-94)           | 81 (65-92)           | 90 (83-95)   | 77 (64-86)   |
|                     |                                   |                    | ≥9.44     | 62  | 4   | 13  | 33  | 83 (72-90)           | 89 (75-97)           | 94 (86-98)   | 72 (60-81)   |
| Alkhouri, 2011      | ELF test                          | 0.924 (0.869-0.978)| ≥8.49d   | 58  | 1   | 18  | 34  | 76 (65-85)           | 97 (85-100)          | 98 (89-100)  | 65 (56-74)   |
|                     |                                   |                    | ≥9.28     | 16  | 0   | 60  | 35  | 21 (13-32)           | 100 (90-100)         | 100          | 37 (34-40)   |

*Continues*
### TABLE 2 (Continued)

| Study             | Test                          | AUC (95% CI) | Threshold | TP  | FP  | FN  | TN  | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|-------------------|-------------------------------|--------------|-----------|-----|-----|-----|-----|----------------------|----------------------|--------------|--------------|
| Schwimmer, 2017   | MRE                           | 0.777        | ≥2.69 kPa | 17  | 6   | 19  | 48  | 44 (30-62)           | 91 (80-97)           | 76 (53-92)   | 71 (59-81)   |
|                   |                               |              | Manual, Centre 2 |     |     |     |     |                      |                      |              |              |
|                   |                               |              | ≥2.77 kPa  | 16  | 5   | 20  | 49  | 44 (28-62)           | 91 (80-97)           | 76 (53-92)   | 71 (59-81)   |
|                   |                               |              | Manual, Centre 1 |     |     |     |     |                      |                      |              |              |
|                   |                               |              | ≥2.78 kPa  | 16  | 5   | 20  | 49  | 44 (28-62)           | 91 (80-97)           | 76 (53-92)   | 71 (59-81)   |
|                   |                               |              | Automated reading |     |     |     |     |                      |                      |              |              |
| Hudert, 2019      | MRE                           | 0.790 (0.664-0.917) | ≥1.46 m/s | 25  | 1   | 10  | 14  | 71 (54-85)           | 93 (68-100)          | 96 (79-99)   | 58 (45-71)   |
|                   |                               |              | Manual, Centre 2 |     |     |     |     |                      |                      |              |              |
|                   |                               |              | ≥2.77 kPa  | 16  | 5   | 20  | 49  | 44 (28-62)           | 91 (80-97)           | 76 (53-92)   | 71 (59-81)   |
|                   |                               |              | Manual, Centre 1 |     |     |     |     |                      |                      |              |              |
|                   |                               |              | ≥2.78 kPa  | 16  | 5   | 20  | 49  | 44 (28-62)           | 91 (80-97)           | 76 (53-92)   | 71 (59-81)   |
|                   |                               |              | Automated reading |     |     |     |     |                      |                      |              |              |
| Nobili, 2008      | TE (FibroScan®, M-probe)      | 0.977 (90% CI: 0.90-0.99) | ≥5.1 kPa | 38  | 1   | 1   | 10  | 97 (93-100)          | 91 (77-100)          | 97 (93-100) | 91 (77-100)  |
| Phelps, 2016      | Point SWE (Siemens Acuson S3000) | 0.75 (0.33-1.00) | ≥1.7 m/s | 3   | 0   | 1   | 1   | 75 (19-99)           | 100 (3-100)          | 100          | 50 (15-85)   |
| Garcovich, 2017   | SWE (Aixplorer US system)      | 0.924        | ≥5.1 kPa  | 42  | 1   | 7   | 18  | 86 (73-64)           | 95 (74-100)          | 98 (86-100)  | 72 (56-84)   |
| Hudert, 2018      | Time-harmonic elastography    | 0.883 (0.804-0.963) | ≥1.52 m/s | 37  | 1   | 11  | 18  | 77 (63-88)           | 95 (74-100)          | 97 (85-100)  | 62 (49-74)   |
| Famakis, 2019     | SWE (GE LOGIQ E9 system)      | 0.554 (0.339-0.768) | ≥1.29 m/s | 18  | 8   | 4   | 3   | 83 (60-95)           | 27 (6-61)            | 69 (60-77)   | 43 (17-74)   |

Abbreviations: AUC, area under the receiver operating characteristics curve; CK-18, cytokeratin-18; ELF test, enhanced liver fibrosis test; FN, false negatives; FP, false positives; HA, hyaluronic acid; MRE, magnetic resonance elastography; NPV, negative predictive value; PNFI, paediatric NAFLD fibrosis index; PPV, positive predictive value; TE, transient elastography; TN, true negatives; TP, true positives.

aOptimal threshold aiming for high sensitivity.

bOptimal threshold aiming for high specificity.

cHighest sensitivity with specificity > 90%.

dOptimal threshold when maximizing sensitivity and specificity/Youden index.

eLR + >10.

fPPV 100%.

Method for finding optimal threshold not reported.

Other method for finding optimal threshold.
### TABLE 3  Studies on detecting significant fibrosis

| Study               | Test                                | AUC (95% CI)       | Threshold | TP  | FP  | FN  | TN  | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|---------------------|-------------------------------------|--------------------|-----------|-----|-----|-----|-----|----------------------|----------------------|--------------|--------------|
| **Prediction scores** |                                     |                    |           |     |     |     |     |                      |                      |              |              |
| Alkhouri, 2013      | PNFI                                | 0.747 (0.632-0.820)| ≥8.2b     | 9   | 24  | 1   | 41  | 90 (56-100)          | 63 (50-74)           | 27 (20-35)  | 98 (86-100)  |
| **Biomarkers**      |                                     |                    |           |     |     |     |     |                      |                      |              |              |
| Nobili, 2009        | ELF test                            | 0.98 (0.96-1.00)   | ≥10.09    | 17  | 11  | 0   | 84  | 100 (80-100)         | 88 (80-94)           | 61 (47-73)  | 100          |
| Nobili, 2010        | HA                                  | 0.95 (0.91-0.99)   | ≥2100 ng/mL | 38  | 10  | 7   | 149 | 84 (71-94)          | 94 (89-97)           | 79 (67-88)  | 96 (92-98)   |
| Nobili, 2009        | ELF test                            | 0.98 (0.96-1.00)   | ≥10.18b   | 16  | 7   | 1   | 88  | 94 (71-100)         | 93 (85-97)           | 70 (53-83)  | 99 (93-100)  |
| Fitzpatrick, 2010   | CK-18 (M30)                         | 0.66 (0.5-0.82)    | ≥200 IU/L | 13  | 19  | 2   | 66  | 83 (61-95)          | 41 (21-64)           | 60 (50-68)  | 69 (45-86)   |
| Mosca, 2019         | PIIINP                              | 0.922 (0.871-0.972)| ≥8.89 ng/mL | 38  | 10  | 7   | 149 | 84 (71-94)          | 94 (89-97)           | 79 (67-88)  | 96 (92-98)   |
| **Imaging techniques** |                                    |                    |           |     |     |     |     |                      |                      |              |              |
| Nobili, 2008        | TE (FibroScan®, M-probe)            | 0.992 (90% CI: 0.92-0.99) | ≥7.4 kPa^c^ | 12  | 3   | 0   | 35  | 100 (82-100)        | 92 (82-97)           | 80 (59-92)  | 100 (93-100) |
| Alkhouri, 2013      | TE (FibroScan®, S-probe)            | 1.00 (0.98-1.00)   | ≥8.6 kPa^b^ | 10  | 0   | 0   | 57  | 100 (69-100)        | 100 (94-100)         | 100          |              |
| Trout, 2018         | MRE                                 | 0.53 (0.35-0.71)   | ≥0.94 kPa^a^ | 3   | 0   | 20  | 21  | 13 (3-34)           | 100 (84-100)         | 100          | 51 (47-55)   |
| Hudert, 2019        | Multifrequency MRE                  | 0.907 (0.827-0.986) | ≥1.48 m/s^d^ | 17  | 2   | 6   | 25  | 74 (52-90)          | 93 (76-99)           | 89 (69-97)  | 81 (68-89)   |
| Garcovich, 2017     | SWE (Aixplorer US system)           | 0.966              | ≥6.7 kPa^b^ | 14  | 2   | 2   | 50  | 88 (62-98)          | 96 (87-100)          | 88 (64-99)  | 96 (87-98)   |
| Hudert, 2018        | US time-harmonic elastography       | 0.994 (0.982-1.000)| ≥1.62 m/s^b^ | 30  | 0   | 1   | 36  | 97 (83-100)         | 100 (90-100)         | 100          | 97 (84-100)  |

Abbreviations: AUC, area under the receiver operating characteristics curve; CK-18, cytokeratin 18; ELF test, enhanced liver fibrosis test; FN, false negatives; FP, false positives; HA, hyaluronic acid; MRE, magnetic resonance elastography; NPV, negative predictive value; NR, not reported; PIIINP, procollagen type III amino terminal peptide; PNFI, paediatric NAFLD fibrosis index; PPV, positive predictive value; SWE, shear wave elastography; TE, transient elastography; TN, true negatives; TP, true positives.

^aHighest sensitivity with specificity > 90%.

^bOptimal threshold when maximizing sensitivity and specificity/Youden index.

^cLR > 10.

^dMethod for finding optimal threshold not reported.

^eOther method for finding optimal threshold.
CI: 0.38-1.00). All other prediction scores and biomarkers had AUCs ranging between 0.71 and 0.78, and only single studies were included for each. MRE was evaluated in two studies that both showed good AUCs, but this did not result in a high sensitivity when aiming for a specificity of >90%. The perfect accuracy reported by Nobili et al. for TE of FibroScan® could not be reproduced by Lee et al. None of the studies used an external validation cohort. Only one study performed internal validation using bootstrapping. Lee et al. used a calibration and validation cohort, although this was applied to the entire cohort of children with various liver disease and not to the subgroup of ten children with NAFLD for which we received raw data. Only for the imaging techniques MRE and TE of FibroScan®, multiple studies were included. However, the use of different optimal thresholds precluded pooling their results.

4 | DISCUSSION

To the best of our knowledge, this is the first systematic review on the diagnostic accuracy of fibrosis tests in paediatric NAFLD. We reported the accuracy of fibrosis tests in detecting mild, significant or advanced fibrosis in children with NAFLD using histology as a reference standard. Diagnostic accuracy was determined in 20 studies encompassing a total of 1787 subjects with NAFLD. This systematic review shows that although a wide range of fibrosis tests have been studied in children, robust accuracy data are scarce.

Most included studies had a small sample size; only three studies included more than 200 subjects. Out of the 16 fibrosis tests included in this SR, only two tests (PNFI and ELF) had accuracy data for detecting mild fibrosis in two studies with similar thresholds, validating results for this fibrosis stage. However, the generalizability of these results is still compromised because all studies were performed in the same tertiary liver clinic. In addition, some overlap between cohorts in the studies that evaluated the PNFI cannot be excluded because inclusion periods overlapped. For all other tests and fibrosis stages, no external validation was performed. Comparing the accuracy results of serum biomarkers can be complicated by the use of kits from different manufacturers. In this review, this applies to HA, probably explaining the remarkable difference in thresholds between the three studies. For imaging techniques, comparing accuracy results among studies was further precluded by the use of different techniques and machines. Despite some studies reporting (near) perfect accuracy, due to the virtually complete lack of validation data, the actual accuracy and clinical utility of all fibrosis tests remains uncertain.

The wide range of optimal thresholds reported by the included studies is explained by the high variety in methods to determine this threshold. These include, among others, the Youden index, optimizing sensitivity or specificity, a PPV of 100% and a positive likelihood ratio > 10. Several studies did not report how the optimal threshold was defined or determined it in a cohort of children with various liver diseases. The wide range of reported thresholds shows the lack of consensus on the minimal diagnostic performance of fibrosis tests in NAFLD, while also highlighting the need to report operating characteristics curves and to publish raw study data. In 2018, the LITMUS consortium (Liver Investigation: Testing Marker Utility in Steatohepatitis) published a report describing the minimal acceptable performance criteria in the different possible contexts of use of biomarkers in adult NAFLD (e.g. screening, diagnosing, prognostic and monitoring). Although not aimed at children, these context and criteria are equally relevant in paediatric NAFLD. Future biomarker studies should be designed and reported taking into account applicability and minimal acceptable performance criteria for its intended context of use of the biomarker.

Applicability of the reported study results is compromised by the fact that all included studies were performed in tertiary liver centres, half of those studies originate from the same European centre, and all were performed in severely metabolically affected children who underwent liver biopsy based on clinical grounds. Although the latter is inevitable due to ethical restraints when performing a liver biopsy, it is important to take them into account when considering the applicability of the liver fibrosis tests in other settings, particularly in a screening setting.

A strength of this study is the sensitive and well-defined search strategy that lowered the risk of missing relevant studies. As we anticipated for a low prevalence of fibrosis, we included studies with at least 60 children, to provide a more solid reflection of the test accuracy. However, a lower number of patients was accepted if the index test was evaluated in at least two studies. Included studies with <60 participants evaluated MRE, SWE, TE, HA and CK-18. A limitation of this SR is that summary AUCs or summary sensitivities and specificities could not be calculated for any fibrosis test based on the published data and we did not collect raw data of all included studies.

In conclusion, the available data on the accuracy of non-invasive fibrosis tests in children with NAFLD are insufficient to determine their accuracy. As studies have solely been performed in tertiary care settings, accuracy data cannot directly be translated to screening populations. The most promising tests identified are TE by FibroScan®, ELF test and ultrasound SWE, as they were evaluated in more than one study and showed consistent good performance. Future studies are needed to validate the most promising tests and determine their accuracy in different clinical settings. Future studies should report diagnostic accuracy over the full range of fibrosis grades using standardized outcomes including receiver operating characteristics curves discuss the applicability of the results for its context of use and relate to the minimally acceptable performance of the biomarker for that context as defined by the LITMUS consortium. Collaborations between paediatric centres on an international level, such as the NASH CRN and the paediatric European NAFLD registry, are needed to create a large diverse cohort with well-characterized children with NAFLD.
| Study            | Test                  | AUC (95% CI)      | Threshold | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
|------------------|-----------------------|-------------------|-----------|----|----|----|----|----------------------|----------------------|--------------|--------------|
| **Prediction scores** |                       |                   |           |    |    |    |    |                      |                      |              |              |
| Alkhouri, 2014   | PNFS                  | 0.74 (0.66-0.82)  | ≥8^a       | 35 | 138| 1  | 68 | 97 (85-100)          | 33 (27-40)           | 20 (19-22)   | 96 (91-100) |
|                  |                       |                   | ≥26^b      | 11 | 16 | 25 | 190| 31 (16-48)           | 92 (88-96)           | 41 (26-58)   | 88 (86-90)  |
| **Biomarkers**   |                       |                   |           |    |    |    |    |                      |                      |              |              |
| Nobili, 2009     | ELF test              | 0.99 (0.97-1.00)  | ≥10.51^d   | 8  | 2  | 0  | 102| 100 (63-100)         | 98 (93-100)          | 80 (50-94)   | 100          |
|                  |                       |                   | ≥10.78     | 4  | 1  | 4  | 103| 50 (16-84)           | 99 (95-100)          | 80 (34-97)   | 96 (93-98)  |
|                  |                       |                   | ≥11.56     | 2  | 0  | 6  | 104| 25 (3-65)            | 100 (97-100)         | 100          |              |
| Fitzpatrick, 2012| MCP-1                 | 0.76 (0.62-0.91)  | ≥200 ng/L^a| 12 | 8  | 1  | 19 | 92 (64-100)          | 70 (50-86)           | 60 (45-73)   | 95 (74-99)  |
|                  |                       |                   | ≥52.7 μg/L^a| 11 | 8  | 2  | 19 | 85 (55-98)           | 70 (50-86)           | 58 (42-72)   | 90 (72-97)  |
|                  | PAI-1                 | 0.78 (0.6-0.91)   | ≥34 ng/mL^de| 0  | 0  | 4  | 6  | 0 (0-60)             | 100 (54-100)         | 0            | 60 (60-60)  |
| Lee, 2013        | HA                    | 0.729 (0.379-1.000)| ≥43 ng/mL^de| 7  | 2  | 0  | 195| 100 (59-100)         | 99 (97-100)          | 78 (47-93)   | 100          |
| Mosca, 2019      | PIIINP                | 0.994 (0.984-1.000)| ≥13.2 ng/mL^d| 7  | 2  | 0  | 195| 100 (59-100)         | 99 (97-100)          | 78 (47-93)   | 100          |
| **Imaging techniques** |                   |                   |           |    |    |    |    |                      |                      |              |              |
| Schwimmer, 2017  | MRE                   | 0.925             | ≥3.03 kPa^c| 2  | 5  | 4  | 79 | 33 (4-78)            | 94 (87-98)           | 29 (4-71)    | 95 (88-99)  |
|                  |                       |                   | Manual, Centre 2 | 3  | 7  | 3  | 77 | 50 (12-88)           | 92 (84-97)           | 30 (7-62)    | 96 (89-99)  |
|                  |                       |                   | Manual, Centre 1 | 2  | 8  | 4  | 76 | 33 (4-78)            | 91 (82-96)           | 20 (3-56)    | 95 (88-99)  |
| Hudert, 2019     | MRE                   | 0.895 (0.802-0.988)| ≥1.53 m/s^c| 9  | 3  | 5  | 33 | 64 (35-87)           | 92 (78-98)           | 75 (49-90)   | 87 (76-93)  |
| Lee, 2013        | TE (FibroScan®, M-probe) | 0.625 (0.188-1.000)| ≥8.6 kPa^de| 2  | 1  | 2  | 3  | 50 (7-93)            | 75 (19-99)           | 67 (22-93)   | 60 (33-82)  |
| Nobili, 2008     | TE (FibroScan® M-probe)| 1.00 (90% CI: 0.94-1.00) | ≥10.2 kPa^f| 5  | 0  | 0  | 45 | 100 (65-100)         | 100 (94-100)         | 100 (65-100) | 100 (94-100) |
| Hudert, 2018     | Time-harmonic elastography | 0.880 (0.800-0.960)| ≥1.64 m/s^d| 18 | 10 | 0  | 39 | 100 (81-100)         | 80 (66-90)           | 64 (51-76)   | 100          |

Abbreviations: AUC, area under the receiver operating characteristics curve; ELF test, enhanced liver fibrosis test; FN, false negatives; FP, false positives; HA, hyaluronic acid; MCP-1, monocyte chemoattractant protein 1; MRE, magnetic resonance elastography; NPV, negative predictive value; PAI, plasminogen activator inhibitor 1; PIIINP, procollagen type III amino terminal peptide; PNFS, paediatric NAFLD fibrosis score; PPV, positive predictive value; TE, transient elastography; TN, true negatives; TP, true positives.

^aOptimal threshold aiming for high sensitivity.

^bOptimal threshold aiming for high specificity.

^cHighest sensitivity with specificity > 90%.

^dOptimal threshold when maximizing sensitivity and specificity/Youden index.

^eOptimal threshold found in cohort of children with various liver diseases.

^fLR + >10.

^gMethod for finding optimal threshold not reported.
REGISTRATION

The protocol of this systematic review is available in PROSPERO: CRD42019117504.

PATIENT CONSENT

Not applicable for systematic review.

ACKNOWLEDGEMENT

No funding was received for the purpose of this study.

CONFLICT OF INTEREST

All authors do not have any disclosures to report.

ETHICS APPROVAL

Not applicable for systematic review.

ORCID

Laura G. Draijer https://orcid.org/0000-0002-1840-1692

REFERENCES

1. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54(5):700-713.

2. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0140908.

3. Nobili V, Reale A, Alisi A, et al. Elevated serum ALT in children presenting to the emergency unit: relationship with NAFLD. Dig Liver Dis. 2009;41(10):749-752.

4. Schwimmer JB, Newton KP, Awai H, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38(10):1267-1277.

5. Kohl R, Boyd T, Lake K, et al. Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr. 2010;50(4):453-456.

6. Feldstein AE, Chairatcharoenwittaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58(11):1538-1544.

7. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, MD). 2015;61(5):1547-1554.

8. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625.e1612.

9. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr. 2016;64(2):319-334.

10. Alkhouri N, Kohli R, Feldstein AE. Designing clinical trials in pediatric nonalcoholic steatohepatitis: tips for patient selection and appropriate endpoints. Hepatol Commun. 2019;3(12):1563-1570.

11. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American association for the study of liver D. Liver biopsy. Hepatology (Baltimore, MD). 2009;49(3):1017-1044.

12. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475-485.

13. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology (Baltimore, MD). 2017;66(5):1486-1501.

14. Mansoor S, Collyer E, Alkhouri N. A comprehensive review of non-invasive liver fibrosis tests in pediatric nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2015;17(6):23.

15. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2005;41(6):1313-1321.

16. Medcalc. https://www.medcalc.org/calc/diagnostic_test.php

17. Alkhouri N, Carter–Kent C, Lopez R, et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol. 2011;9(2):150-155.

18. Farmakis SG, Buchanan PM, Guzman MA, Hardy AK, Jain AK, Teckman JH. Shear wave elastography correlates with liver fibrosis scores in pediatric patients with liver disease. Pediatr Radiol. 2019;49(3):1742-1753.

19. Hudert CA, Tzschätzchz H, Guo J, et al. US time-harmonic elastography: detection of liver fibrosis in adolescents with extreme obesity with nonalcoholic fatty liver disease. Radiology. 2018;288(1):99-106.

20. Hudert CA, Tzschätzchz H, Rudolph B, et al. Tomoeastography for the evaluation of pediatric nonalcoholic fatty liver disease. Invest Radiol. 2019;54(4):198-203.

21. Lebensztejn DM, Wierzbicka A, Socha P, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol. 2011;58(4):563-566.

22. Mandelia C, Collyer E, Mansoor S, et al. Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2016;63(2):181-187.

23. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (Baltimore, MD). 2008;49(2):442-448.

24. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009;136(1):160-167.

25. Nobili V, Alisi A, Torre G, et al. Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res. 2010;156(4):229-234.

26. Nobili V, Alisi A, Vania A, Tiribelli A, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7:21.

27. Phelps A, Ramachandran R, Courtier J, Perito E, Rosenthal P, MacKenzie JD. Ultrasound elastography: is there a shear wave speed cutoff for pediatric liver fibrosis and inflammation? Clin Imaging. 2017;41:95-100.

28. Schwimmer JB, Behling C, Angeles JE, et al. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2017;66(5):1474-1485.

29. Trout AT, Sheridan RM, Serai SD, et al. Diagnostic performance of MR elastography for liver fibrosis in children and young adults with a spectrum of liver diseases. Radiology. 2018;287(3):824-832.

30. Mosca A, Comparcola D, Romito I, et al. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity
in children with non-alcoholic fatty liver disease. Liver International. 2019;39(12):2317-2329.

31. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (Baltimore, MD). 2008;48(1):119-128.

32. Garcovcich M, Veraldi S, Di Stasio E, et al. Liver stiffness in pediatric patients with fatty liver disease; diagnostic accuracy and reproducibility of shear-wave elastography. Radiology. 2017;283(3):820-827.

33. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010;51(4):500-506.

34. Alkhouri N, Sedki E, Alisi A, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33(1):79-85.

35. Alkhouri N, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One. 2014;9(8):e104558.

36. Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatric obesity. 2012;7(6):471-479.

37. Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children’s hospital experience. The Journal of Pediatrics. 2013;163(4):1058-1064 e1052.

38. LITMUS. Report describing minimally acceptable performance criteria for diagnostic testing. 2018.

39. Mann JP, Vreugdenhil A, Socha P, et al. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): design and rationale. Contemp Clin Trials. 2018;75:67-71.

40. Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric non-alcoholic steatohepatitis. Gastroenterology. 2008;135(6):1961-1971. e1962.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Draijer LG, van Oosterhout JPM, Valiy Y, et al. Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review. Liver Int. 2021;00:1-14. https://doi.org/10.1111/liv.14908